GlassScriptPhysician profile
Baltazar Orallo
NPI 1013989524
$10,822.35
in general payments reported to CMS, 2019-2025
46 companies · $1,071 in 2025
The $1,071 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,171 · 2020: $656 · 2021: $1,522 · 2022: $1,878 · 2023: $1,902 · 2024: $1,621 · 2025: $1,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,509 · Education: $86.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,508.95 |
| Education | $86.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,269.55 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,288.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $787.71 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $676.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $669.87 | 2021-2025 | |
| Pfizer INC. | $655.46 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $647.90 | 2019-2025 | Ofev, Jardiance, Jascayd |
| Janssen Pharmaceuticals, INC | $552.43 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $497.71 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Astellas Pharma US INC | $341.46 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $282.49 | 2019-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $225.18 | 2021 | |
| Amgen INC. | $213.80 | 2019-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $175.40 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.24 | 2022-2025 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baltazar Orallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.